Search
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[L48181] Ritlecitinib is administered orally and is the first member of its class. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: 2-propen-1-one, 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-D)pyrimidin-4-ylamino)-1-piperidinyl)-Pyrotinib
go.drugbank.com/drugs/DB14993InvestigationalPyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Categories: Heterocyclic Compounds, 2-RingDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalDaridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. … It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[L10169] It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. … trial whose tumour is entirely or partially destroyed by a drug.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexMipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Categories: P-glycoprotein substratesSynonyms: (3.BETA.)-CHOLEST-5-EN-3-YL 3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)PYRIDIN-4-YL CARBONATE, CHOLEST-5-EN-3-OL (3.BETA.)-, 3-(3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)-4-PYRIDINYL CARBONATE)Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid … Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsDexpramipexole
go.drugbank.com/drugs/DB15130InvestigationalFrom the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)). … Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. … [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalDeutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors